Evonik Invests $108M in Vancouver Lipid-Drug Manufacturing Facility
- Evonik is building a new GMP drug-product facility in Vancouver with CAD 150M ($108M) investment, supported by CAD 68M ($49M) in Canadian federal funding.
- The facility will deliver 3× current capacity for lipid-based drug delivery and launch commercial production by end of 2029.
- Expanded quality control and microbiological testing capabilities will support clinical and commercial-scale development for pharma and biotech customers.
Operational Impact
Evonik's Vancouver facility adds significant APAC-adjacent lipid-drug-product capacity by 2029, reducing regional bottlenecks for biotech sponsors scaling lipid-based programs toward commercial launch.
Source: PharmaSource RSS
Ennolys Expands CDMO Services in Fermentation, DSP, and Drying
- Ennolys is expanding CDMO capabilities to cover fermentation, downstream processing (DSP), and drying for biotech projects from R&D through commercial production.
- The service leverages 30+ years of fermentation expertise and large-capacity fermenters to optimize yields, quality, and reproducibility for enzymes, probiotics, proteins, and peptides.
- Expansion aims to help manufacturers reduce development costs, accelerate time to market, and secure supply chains across food, cosmetics, nutraceuticals, and animal nutrition markets.
Operational Impact
Ennolys's expanded fermentation and DSP capabilities add CDMO capacity for biotech manufacturers seeking integrated development-to-production support, particularly for fermentation-derived biologics and metabolites in food, cosmetics, and nutraceutical markets.
Source: PharmaSource RSS